Results 31 to 40 of about 49,130 (295)

ICD Outcome in Pediatric Cardiomyopathies

open access: yesJournal of Cardiovascular Development and Disease, 2022
Background: Pediatric patients with cardiomyopathies are at risk of malignant arrhythmias and sudden cardiac death (SCD). An ICD may prevent SCD. The aim of this study was to evaluate ICD implantation outcomes, and to compare transvenous and subcutaneous
Massimo Stefano Silvetti   +10 more
doaj   +1 more source

Overview of Cardiomyopathies in Childhood

open access: yesFrontiers in Pediatrics, 2021
Paediatric cardiomyopathies are a heterogenous group of rare disorders, characterised by mechanical and electrical abnormalities of the heart muscle. The overall annual incidence of childhood cardiomyopathies is estimated at about 1 per 100,000 children ...
Anika Rath   +3 more
doaj   +1 more source

Eclipsed Functional Mitral Regurgitation Destabilizing Hypertrophic Cardiomyopathy: An Unusual Case Treated With MitraClipNovel Teaching Points

open access: yesCJC Open, 2021
MitraClip (Abbott Laboratories, Abbott Park, IL) is validated in high-risk patients with severe degenerative mitral regurgitation (MR); however, it is not well established for functional MR in hypertrophic cardiomyopathy (HCM).
Catherine Bourque, MD   +8 more
doaj   +1 more source

Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort

open access: yesReviews in Cardiovascular Medicine
Background: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM).
Ali Amr   +7 more
doaj   +1 more source

A very rare cause of pre‐capillary pulmonary hypertension: The PAMI syndrome

open access: yesPulmonary Circulation, 2023
We report the first known case of PAMI syndrome associated with pulmonary arterial hypertension (PAH) with a positive response to cyclophosphamide and pulmonary vasodilators. The patient's history began at 7 months with severe pancytopenia and fever.
Manuela Iseppi   +5 more
doaj   +1 more source

Antithrombotic treatment in cardiomyopathies

open access: yes, 2020
Cardiomyopathies are a heterogeneous group of heart muscle diseases and important cause of heart failure with reduced or preserved ejection fraction. Although there is an increasing body of evidence on the incidence, pathophysiology, and natural history ...
Tousoulis, D.   +2 more
core   +1 more source

Human-induced pluripotent stem cells in modeling inherited cardiomyopathies

open access: yesJournal of the Practice of Cardiovascular Sciences, 2015
Our current understanding of molecular mechanisms of cardiomyopathies has been elucidated from genetic animal models. Induced pluripotent stem cells (iPSCs) can provide a platform to improve our understanding of familial cardiomyopathies diseases.
Subhoshree Ghose   +3 more
doaj   +1 more source

Epidemiology and Clinical Aspects of Genetic Cardiomyopathies [PDF]

open access: yes, 2018
Cardiomyopathies are an increasingly recognized cause of heart failure and sudden death, particularly in young patients. Since their original description, major advances were achieved in the phenotype knowledge (i.e.
Masarone, D   +27 more
core   +2 more sources

Lysyl oxidase (LOX)‐mediated remodeling of the extracellular matrix

open access: yesFEBS Letters, EarlyView.
The lysyl oxidase (LOX) family of enzymes drives extracellular matrix remodeling by oxidizing collagen, elastin, and fibronectin, promoting covalent cross‐link formation. This activity regulates tissue architecture and mechanical properties, while its dysregulation contributes to fibrosis, cardiovascular disease, glaucoma, connective tissue disorders ...
Fernando Rodríguez‐Pascual   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy